Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2015

01.01.2015 | Original Article

Intestinal Microbiota Transplantation, a Simple and Effective Treatment for Severe and Refractory Clostridium Difficile Infection

verfasst von: Hadeel Zainah, Mona Hassan, Laila Shiekh-Sroujieh, Syed Hassan, George Alangaden, Mayur Ramesh

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Restoring normal fecal flora through intestinal microbiota transplantation (IMT) was successful in curing recurrent Clostridium difficile infection (CDI). However, only a few cases have been reported of IMT being utilized for the treatment of severe or fulminant CDI.

Aim

Is IMT a simple and effective treatment for severe and recurrent CDI?

Methods

In this retrospective study, we report 14 patients with severe CDI refractory to conventional medical therapy, who underwent IMT. Fresh donor stool specimen was manually homogenized with warm tap water, filtered through gauze and then instilled through nasogastric tube (NGT). The primary outcome was clinical cure, defined as less than 3 loose bowel movements a day on day 7 after IMT and no need for further CDI therapy. The secondary outcomes were recurrence of CDI within 100 days of IMT and 30-day mortality after IMT. Descriptive statistics were done.

Results

Fourteen patients with severe and refractory CDI received IMT. Mean age was 73.4 ± 11.9 years (range 52–92). IMT was given via NGT in 13 of the 14 patients. Eleven patients (79 %) achieved cure after IMT. No recurrence was seen in the patients who responded to IMT and were alive within the 100 day follow-up period. IMT was well tolerated. The 30-day all-cause mortality was 29 %, all 4 patients died as a result of their underlying cancer. No patients died as a result of CDI or IMT.

Conclusions

IMT performed at the bedside via NGT is effective and safe for the treatment of severe and refractory CDI, and prevents recurrence.
Literatur
1.
Zurück zum Zitat Tabak YP, Zilberberg MD, Johannes RS, et al. Attributable burden of hospital-onset Clostridium difficile infection: a propensity score matching study. Infect Control Hosp Epidemiol. 2013;34:588–596.CrossRefPubMed Tabak YP, Zilberberg MD, Johannes RS, et al. Attributable burden of hospital-onset Clostridium difficile infection: a propensity score matching study. Infect Control Hosp Epidemiol. 2013;34:588–596.CrossRefPubMed
2.
Zurück zum Zitat Van Nood E, Vreize E, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med. 2013;368:407–415.CrossRefPubMed Van Nood E, Vreize E, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med. 2013;368:407–415.CrossRefPubMed
3.
Zurück zum Zitat Gough E. Systematic review of intestinal microbiota transplantation (Fecal Bacteriotherapy) for recurrent clostridium difficile infection. Clin Infect Dis. 2011;53:994–1002.CrossRefPubMed Gough E. Systematic review of intestinal microbiota transplantation (Fecal Bacteriotherapy) for recurrent clostridium difficile infection. Clin Infect Dis. 2011;53:994–1002.CrossRefPubMed
4.
Zurück zum Zitat Grehan MJ, Borody TJ, Leis SM, et al. Durable alteration of the colonic microbiota by administration of donor flora. J Clingastroenterol. 2010;44:551–561. Grehan MJ, Borody TJ, Leis SM, et al. Durable alteration of the colonic microbiota by administration of donor flora. J Clingastroenterol. 2010;44:551–561.
5.
Zurück zum Zitat Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854–859.PubMed Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854–859.PubMed
6.
Zurück zum Zitat Zar FA. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302–307.CrossRefPubMed Zar FA. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302–307.CrossRefPubMed
7.
Zurück zum Zitat Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55:S154–S161.PubMedCentralCrossRefPubMed Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55:S154–S161.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Crawford T, Huesqen E, Danziqer L. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm. 2012;69:933–943.CrossRefPubMed Crawford T, Huesqen E, Danziqer L. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm. 2012;69:933–943.CrossRefPubMed
9.
Zurück zum Zitat Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044–1049.PubMedCentralCrossRefPubMed Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044–1049.PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Reeves AE, Theriot CM, Bergin IL, et al. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes. 2011;2:145–158.PubMedCentralCrossRefPubMed Reeves AE, Theriot CM, Bergin IL, et al. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes. 2011;2:145–158.PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile- associated diarrhea. J Infect Dis. 2008;197:435–438.CrossRefPubMed Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile- associated diarrhea. J Infect Dis. 2008;197:435–438.CrossRefPubMed
14.
Zurück zum Zitat You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med. 2008;148:632–633.CrossRefPubMed You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med. 2008;148:632–633.CrossRefPubMed
15.
Zurück zum Zitat Gallegos-Orozco JF, Paskvan-Gawryletz CD, Gurudu SR, et al. Successful colonoscopic fecal transplant for severe acute Clostridium difficile. Rev Gastroenterol Mex. 2012;77:40–42.PubMed Gallegos-Orozco JF, Paskvan-Gawryletz CD, Gurudu SR, et al. Successful colonoscopic fecal transplant for severe acute Clostridium difficile. Rev Gastroenterol Mex. 2012;77:40–42.PubMed
16.
Zurück zum Zitat Trubiano, JA, Gardiner B Kwong JC et al. Fecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol. 2013;25:255–257. Trubiano, JA, Gardiner B Kwong JC et al. Fecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol. 2013;25:255–257.
17.
Zurück zum Zitat Weingarden AR, Hamilton MJ, Sadowsky MJ, et al. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol. 2013; (Epub ahead of print). Weingarden AR, Hamilton MJ, Sadowsky MJ, et al. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol. 2013; (Epub ahead of print).
18.
Zurück zum Zitat Neemann K, Eichele DD, Smith PW, et al. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012;14:E161–E165.CrossRefPubMed Neemann K, Eichele DD, Smith PW, et al. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012;14:E161–E165.CrossRefPubMed
19.
Zurück zum Zitat Zainah H, Silverman A. Fecal bacteriotherapy: a case report in an immunosuppressed patient with ulcerative colitis and recurrent Clostridium difficile infection. Case Rep Infect Dis.. 2012;2012:810943.PubMedCentralPubMed Zainah H, Silverman A. Fecal bacteriotherapy: a case report in an immunosuppressed patient with ulcerative colitis and recurrent Clostridium difficile infection. Case Rep Infect Dis.. 2012;2012:810943.PubMedCentralPubMed
20.
Zurück zum Zitat Jarchum I, Liu M, Lipuma L et al. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immun. 79:1498–1503. Jarchum I, Liu M, Lipuma L et al. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immun. 79:1498–1503.
21.
Zurück zum Zitat Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile Infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–455. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile Infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–455.
22.
Zurück zum Zitat McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile–associated disease. Infect Control Hosp Epidemiol. 2007;28:140–145.CrossRefPubMed McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile–associated disease. Infect Control Hosp Epidemiol. 2007;28:140–145.CrossRefPubMed
23.
Zurück zum Zitat Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: “first-line” treatment for severe Clostridium difficile infection? J Clin Gastroenterol. 2011;45:655–657.CrossRefPubMed Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: “first-line” treatment for severe Clostridium difficile infection? J Clin Gastroenterol. 2011;45:655–657.CrossRefPubMed
Metadaten
Titel
Intestinal Microbiota Transplantation, a Simple and Effective Treatment for Severe and Refractory Clostridium Difficile Infection
verfasst von
Hadeel Zainah
Mona Hassan
Laila Shiekh-Sroujieh
Syed Hassan
George Alangaden
Mayur Ramesh
Publikationsdatum
01.01.2015
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2015
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3296-y

Weitere Artikel der Ausgabe 1/2015

Digestive Diseases and Sciences 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.